Pinc PeptideThe girly peptide research blog

Compare · updated 8 October 2026

BPC-157 vs TB-500

The short answer

BPC-157 and TB-500 are two different unapproved peptides sold for injury healing, and neither has been shown to heal injuries in people12. The five small published studies of BPC-157 that FDA found gave it to fewer than 100 people, for 2 weeks or less, while FDA found no study that gave TB-500 to people, and neither did our PubMed search123. In a 2026 rat study of Achilles tendon repair that tested both, the peptide its authors called synthetic thymosin beta-4 (TB-500) alone made tendons stronger, BPC-157’s gains were not statistically significant, and combining them added no benefit4.

At a glance

ComparedBPC-157TB-500
Evidence tierB At least one controlled human trialD Animal studies only
Does it work?For tendon and joint healing: UntestedFDA found no controlled human trial of it for tendons or joints; those claims rest on animal studies15. The only controlled trial in patients that FDA found, for a bowel disease, showed no clear benefit1.For tendon, ligament, muscle and bone healing: UntestedNeither FDA’s review nor our PubMed search found a study in people23. Healing claims rest on a few animal and cell studies with mixed results; the tendon study called its peptide synthetic thymosin beta-4246.
FDANot approved for any use1Not approved for any use2
US pharmaciesPharmacies may not make it7Pharmacies may not make it278
SportBanned at all times9Banned at all times9
AustraliaPrescription only; illegal to hold without one10Prescription only; illegal to hold without one10
Half-lifeAbout 15 minutes in rats and 5 minutes in dogs after an IV dose; unknown in humans11No human value found2
Taken asSubcutaneous injection (not used in any clinical study FDA found)
Oral capsules, tablets, gummies and sprays (sold as supplements and compounded products; a 2015 oral study and a 2025 gummy study have posted no results)
Nasal spray (no human data found)
Intramuscular injection (animal studies only)
Rectal enema (human studies reported 2002 to 2005)
Knee (intra-articular) injection (retrospective case series)
Injection into the bladder wall (single-arm pilot)
Intravenous infusion (2-person pilot)
Transdermal cream (proposed in a withdrawn compounding nomination; no human data found)		Subcutaneous injection (the usual community route; no human data found; the only drug-level data we found are from horses)
Intramuscular injection (proposed in the withdrawn compounding nomination; no human data or animal drug-level data found)
Intraperitoneal injection (rats only)
Nasal spray (sold in blends with BPC-157; no data found)
Topical (only the non-acetylated fragment, in mice)
What it isA 15-amino-acid peptide described as a fragment of a protein from human gastric juice112.A 7-amino-acid fragment (positions 17 to 23) of thymosin beta-4, a 43-amino-acid protein; FDA says the two are not the same substance2.
How it might workUnknown; animal and cell studies suggest new blood-vessel growth, nitric oxide production and dampened inflammation113.Unknown; in a cell test, TB-500 itself did not speed the closing of scratch wounds, while one of its breakdown products had a small effect26.
Studied in people forUlcerative colitis (as an enema), knee pain, bladder pain and IV safety, in the published studies FDA found, which gave it to fewer than 100 people in all; an 8-week study of gummies has posted no results, and a trial after rotator cuff surgery is not due to start until January 202711415161718.Nothing: FDA found no clinical trial, case report or other human data for TB-500 by any route2.
Best human evidenceOne randomized trial, in 53 people with ulcerative colitis, which found no statistically significant benefit1.None; trials of full-length thymosin beta-4, such as a 700-person eye-drop study, tested a different molecule219.
Biggest documented riskUnknown human safety; in 28-day animal studies it changed blood clotting and raised liver-related blood levels120.FDA found no human or animal safety data, including no cancer studies; a possible cancer signal dominated discussion at FDA’s 2026 panel, according to the FDA Law Blog221.
Lab tests of gray-market vials92 of Finnrick’s latest 200 tests failed (27 May to 25 September 2026), and a bodega vial tested for WIRED held no BPC-1572223.113 of Finnrick’s latest 200 tests failed (29 January to 25 September 2026), and a 2023 lab study found contents did not always match product descriptions2425.

Is there evidence for taking them together?

FDA’s reviews found no human study of BPC-157 and TB-500 together12. In a 2026 study of rats with repaired Achilles tendons (8 per group), TB-500 alone gave stronger tendons, BPC-157’s gains were not statistically significant, and combining the two added no benefit over either alone4. The authors called the study exploratory and described their TB-500 as ‘synthetic thymosin beta-4’, so it may have been the full protein rather than the fragment, and earlier rat work had reported faster Achilles healing with BPC-157 alone426.

The nearest human data come from a 2021 chart review at a Florida clinic: 3 of 4 knee-pain patients given BPC-157 plus ‘TB4’ said their pain improved, but there was no control group14. The paper and FDA’s BPC-157 review both name the second peptide as thymosin beta-4, not TB-500114.

FDA has also described a report from a 40-year-old woman who injected a BPC-157 and TB-500 ‘research purposes only’ product: her skin and gums darkened, the reaction returned when she used it again, and FDA could not tell which peptide was responsible1.

What is the ‘Wolverine stack’?

‘Wolverine stack’ is a popular name for BPC-157 paired with TB-500, and at least one seller offers both in a single vial holding 10 mg of each2728. Supporters described the pairing to FDA’s advisory panel in July 202621.

Other blends add more peptides: In December 2025 Health Canada reported seizing products sold as ‘Glow’ (BPC-157, TB-500 and GHK-Cu) and ‘Klow’ (the same plus KPV)29. FDA also found nasal sprays that combine BPC-157 with a thymosin beta-4 fragment1.

Interest is growing: ‘wolverine stack’ was among the rising US Google searches related to BPC-157 in the year to 29 September 2026, and a health-records analysis reported by Reuters found new BPC-157 users up 33-fold from 2020 to 2026, in a preprint that has not been peer reviewed2830.

Questions people ask

What are the differences between TB-500 and BPC-157?

They are different molecules: BPC-157 is a 15-amino-acid peptide described as a fragment of a gastric-juice protein, while TB-500 is a 7-amino-acid fragment of thymosin beta-412. BPC-157 has five small human studies, and FDA found no human data at all for TB-50012. Neither is an approved drug, and both are banned in sport129.

Should I take TB 500 with BPC-157?

FDA’s reviews found no human study of the pair, and in a 2026 rat tendon study adding BPC-157 to TB-500 gave no extra benefit24. FDA has a report of skin and gum darkening in a woman who injected a combined product, and it could not tell which peptide caused it1. Neither peptide is an approved drug, and US pharmacies may not compound either1278.

Which is better for tendon injuries, BPC-157 or TB-500?

FDA found no controlled human trial of either for a tendon injury, and a BPC-157 trial after rotator cuff surgery is not due to start until January 20271218. In rats, earlier work reported faster Achilles healing with BPC-157, but a 2026 rat study found that only TB-500, which its authors called synthetic thymosin beta-4, significantly improved tendon strength426.

Has TB-500 been tested in people?

No: FDA’s 2026 review found no clinical trial, case report or other human data for TB-500 by any route, and a PubMed search on 8 October 2026 found no study either23. Trials of full-length thymosin beta-4, a different molecule, include a 700-person eye-drop study that, its maker said, did not meet its main goals; results posted on 28 August 2026 show similar average changes on the drops and on placebo1931.

Go deeper

Sources

  1. 1FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: BPC-157-related bulk drug substances U.S. Food and Drug Administration, 11 May 2026. fda.gov
  2. 2FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: TB-500-related bulk drug substances U.S. Food and Drug Administration, 15 May 2026. fda.gov
  3. 3PubMed search: TB-500, TB500, TB 500 or Ac-LKKTETQ in titles and abstracts (33 results; none gave TB-500 to people) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
  4. 4Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Joint Diseases and Related Surgery, 23 Jul 2026. pubmed.ncbi.nlm.nih.gov
  5. 5Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS Journal, Nov 2025. pubmed.ncbi.nlm.nih.gov
  6. 6Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro Journal of Chromatography B, 1 Mar 2024. pubmed.ncbi.nlm.nih.gov
  7. 7Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  8. 8The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 28 Jul 2026. thefdalawblog.com
  9. 9World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  10. 10Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
  11. 11Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs Frontiers in Pharmacology, 2022. pubmed.ncbi.nlm.nih.gov
  12. 12A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC Journal of Physiology, Paris, 1993. pubmed.ncbi.nlm.nih.gov
  13. 13Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation Journal of Molecular Medicine, Mar 2017. pubmed.ncbi.nlm.nih.gov
  14. 14Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Alternative Therapies in Health and Medicine, Jul 2021. pubmed.ncbi.nlm.nih.gov
  15. 15Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Alternative Therapies in Health and Medicine, Oct 2024. pubmed.ncbi.nlm.nih.gov
  16. 16Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Alternative Therapies in Health and Medicine, Sep 2025. pubmed.ncbi.nlm.nih.gov
  17. 17A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery (NCT07752381) ClinicalTrials.gov, 7 Aug 2026. clinicaltrials.gov
  18. 18Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (NCT07803250) ClinicalTrials.gov, 3 Sep 2026. clinicaltrials.gov
  19. 19Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3, NCT03937882 ClinicalTrials.gov, 28 Aug 2026. clinicaltrials.gov
  20. 20Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds Regulatory Toxicology and Pharmacology, Jul 2020. pubmed.ncbi.nlm.nih.gov
  21. 21PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 24 Jul 2026. thefdalawblog.com
  22. 22BPC-157 Safety Testing Results & Vendor Ratings Finnrick, 29 Sep 2026. finnrick.com
  23. 23Those Viral Bodega Peptides Aren’t Actually Peptides WIRED, 15 Sep 2026. wired.com
  24. 24TB-500: safety testing results and vendor ratings Finnrick, 25 Sep 2026. finnrick.com
  25. 25TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs Drug Testing and Analysis, Apr 2023. pubmed.ncbi.nlm.nih.gov
  26. 26Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth Journal of Orthopaedic Research, Nov 2003. pubmed.ncbi.nlm.nih.gov
  27. 27BPC-157 10mg + TB-500 10mg (Wolverine Stack 20mg) Ascension Peptides (vendor), accessed 1 Oct 2026. ascensionpeptides.com (seller page, deliberately not linked)
  28. 28Use of experimental ‘Wolverine’ peptide backed by RFK Jr is on the rise, study finds The Independent (Reuters), 16 Sep 2026. independent.co.uk
  29. 29Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks (RA-81403) Health Canada, 24 Dec 2025. recalls-rappels.canada.ca
  30. 30Google Trends: rising related queries for ‘bpc 157’, United States, 12 months to 29 September 2026 Google Trends, accessed 30 Sep 2026. trends.google.com
  31. 31RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial RegeneRx Biopharmaceuticals (PR Newswire), 18 Mar 2021. prnewswire.com

Not medical advice. Neither compound is recommended here. How we grade evidence · Report an error.